Quest Diagnostics Hikes Dividend 7.5% After $8.75 EPS in 2025
Quest Diagnostics (NYSE: DGX) rewarded shareholders with a 7.5% dividend increase and a new $1 billion share repurchase authorization on February 10, 2026, following the completion of its 2025 fiscal year that delivered earnings per share of $8.75.
The medical diagnostics giant raised its quarterly dividend from $0.80 to $0.86 per share, marking a significant increase that reflects management's confidence in the company's cash generation capabilities. The new dividend will be payable on April 20, 2026, to shareholders of record as of April 6, 2026.
Key Numbers
Quest Diagnostics reported full-year 2025 earnings per share of $8.75, supported by net income of $990 million for the year. The company's quarterly performance showed consistency throughout 2025, with third-quarter earnings reaching $6.57 per share on net income of $750 million.
The earnings trajectory through 2025 demonstrated the company's operational strength in the core laboratory testing business. Second-quarter 2025 delivered $4.41 in earnings per share with net income of $500 million, while an additional third-quarter report showed $2.16 per share on $240 million in net income.
The 7.5% dividend increase to $0.86 per share translates to an annual dividend of $3.44, up from the previous annual rate of $3.20. For investors holding 100 shares, this means an additional $24 in annual dividend income. The percentage increase notably exceeds the typical 3-5% annual dividend growth seen across the healthcare sector.
The new $1 billion share repurchase authorization adds to Quest's existing buyback program, providing the company with additional flexibility to return capital to shareholders. At current market prices, this authorization could retire approximately 2-3% of outstanding shares, providing support for earnings per share growth even if net income remains flat.
What Management Said
While the 8-K filing did not include detailed management commentary beyond the announcement itself, the Board of Directors' decision to simultaneously increase both the dividend and share repurchase authorization sends a clear message about the company's financial health and future prospects.
The authorization language specifically notes that the Board "authorized the Company to repurchase an additional $1 billion" as part of the ongoing program, indicating this supplements rather than replaces existing buyback capacity. This suggests management sees the current share price as attractive for capital deployment.
The timing of these shareholder-friendly actions, coming alongside the full-year 2025 results announcement, indicates management's satisfaction with the company's performance and outlook for continued cash generation in 2026.
What to Watch
Investors should monitor several key factors as Quest Diagnostics moves through 2026. The company's ability to sustain its $8.75 annual earnings per share level will be critical for supporting the increased dividend payout. With the new annual dividend of $3.44 per share, the payout ratio stands at approximately 39% based on 2025 earnings, leaving substantial room for further increases if earnings grow.
The execution pace of the $1 billion buyback program will provide insights into management's view of valuation and capital allocation priorities. Aggressive buyback activity could signal confidence in near-term business trends, while a measured approach might suggest management is preserving flexibility for potential acquisitions or organic growth investments.
Laboratory testing volumes and reimbursement rates remain critical variables for Quest's financial performance. Any shifts in healthcare utilization patterns, changes in government or commercial payer reimbursement policies, or competitive dynamics in the diagnostic testing market could impact the company's ability to maintain its current earnings trajectory.
The sustainability of the 7.5% dividend growth rate deserves attention. If Quest can maintain similar increases annually, the dividend could double within a decade, making the stock increasingly attractive to income-focused investors. However, such growth requires consistent earnings expansion or a willingness to increase the payout ratio over time.
With net income of nearly $1 billion in 2025 and strong per-share metrics, Quest Diagnostics appears well-positioned to continue returning capital to shareholders. The combination of dividend growth and share repurchases provides multiple paths for shareholder value creation, though investors should continue monitoring quarterly results for signs of operational momentum or challenges in the core testing business.
*Source: Quest Diagnostics Form 8-K filed February 10, 2026*
*StockCliff Research*